Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-

Where to Inject KLOW Peptide: Abdomen or Thigh?
KLOW is given into the fatty layer beneath the skin, usually in an abdomen or thigh area named in the pharmacy directions. The exact boundaries and rotation plan come from the prescription, not from an online diagram.
-

There Is No Best BPC-157 Brand. Ask This Instead.
No company holds an approval to make BPC-157, so the “brands” ranked online are websites, not manufacturers. What's worth comparing is the pharmacy and the prescription behind the vial.
-

Selank Dosage: What Human Studies Actually Used
Russian human studies most clearly report 2.7 mg per day intranasally for 14 days, but that fixed study protocol is not a personal dosing guide and does not convert to an injectable Semax/Selank blend.
-

Semaglutide and Kidney Disease: The Full Picture
In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.
-

SS-31 and MOTS-c: Can You Take Them Together?
They are both mitochondrial peptides, and that is about where the similarity stops. No published trial has given people both at once — here is what each one has behind it.
-

Tirzepatide and Blood Pressure: Does It Lower It?
Yes—blood pressure often falls during tirzepatide treatment, mostly alongside weight loss. That can be welcome, but it also means people taking blood-pressure medicine may need closer review if lightheadedness starts.
-

Tirzepatide and Gallbladder Risk: Small but Real
Gallstones turn up in about 1 in 100 people on tirzepatide in the trials — barely above placebo — but inflamed gallbladders are three and a half times as common. Here is why, and the pain pattern that means call someone today.
-

Tirzepatide and Menopause: What the Evidence Says
Menopause does not appear to stop tirzepatide from working for weight management. The useful question is whether it fits the whole health picture, including sleep, muscle, bone and any hormone therapy already in use.
-

Tirzepatide Psoriasis Data Don’t Make It a Treatment
New 52-week data found better skin and joint outcomes when branded tirzepatide was added to Taltz in adults with psoriatic disease and obesity. That supports treating two linked conditions together—not using tirzepatide alone for psoriasis.
-

When to Take MOTS-c: What Human Research Says
No human trial has shown that morning, night, or a workout window is best. The exercise link is real but easy to overread: researchers measured the MOTS-c people made themselves, not the effect of a timed dose.
-

BPC-157 WADA Status: Prohibited All Year Round
If you're tested in your sport, the answer is short. BPC-157 is prohibited all year round, a prescription doesn't change that, and the one exemption that could is unlikely to be granted, by USADA's own account.
-

Compounded Medication Recall: Check the Lot
A recall usually applies to one pharmacy, one preparation and specific lot numbers—not every compounded medication. Here is how to check a vial and reach the people responsible for it.
-

How to Use PT-141: It's As-Needed, Not Daily
PT-141 is taken before anticipated activity rather than on a daily schedule. Here is what the approved label sets out, what a compounded vial changes, and what the prescriber decides.
-

Kisspeptin-54 vs Kisspeptin-10: Why Length Matters
Kisspeptin-54 is the whole peptide; kisspeptin-10 is its last ten amino acids. The long one lasts about seven times longer in the blood, and that one fact explains which studies used which.
-

MOTS-c Cycle: Nobody Has Established One
The word “cycle” came from bodybuilding, not from any MOTS-c research. Every study that has actually given the peptide — the mouse work, and the one human trial now running — dosed it straight through, with no weeks off.
-

Tesamorelin Cost: Brand vs. Compounded Prices
Public brand benchmarks run from about $6,000 a month at wholesale list price to roughly $10,709 for a 28-day cash quote. Insurance may bring that down for HIV-associated lipodystrophy; compounded tesamorelin follows a separate cash-pay path.
-

How to Get Sermorelin Prescribed: Four Steps
Getting a sermorelin prescription starts with a compound-specific medical intake, followed by a real clinician's review. Symptoms and labs can inform the decision, but neither guarantees a prescription.
-

BPC-157 Dosage by Body Weight: No Human Formula
There is no validated weight-based BPC-157 dose for people. The micrograms-per-kilogram numbers online were lifted from rat experiments, not human dose-finding trials.
-

GHK-Cu Studies Find a Gap in Human Evidence
A new systematic review found only two randomized human GHK-Cu trials among 20 eligible studies, and both were topical. The injectable claims run well ahead of the clinical evidence.
-

Is Sermorelin a Steroid? No, It Is a Peptide
Sermorelin is a peptide signal that asks the pituitary to release growth hormone. It is neither an anabolic steroid nor HGH itself, though sports drug-testing rules still matter.
Page 4 of 12 · 227 articles